Developmental Outcomes of Prenatal Exposure to MDMA ('E*

描述：(申请人提供) 3-4亚甲基二氧基甲基苯丙胺(MDMA/摇头丸)的使用在年轻人中很普遍 欧洲各地的成年人和美国越来越受欢迎的人 在相似的人群中产生了对长期负面影响的担忧 胎儿接触MDMA对发育中儿童的影响MDMA的使用也是 与其他可能对儿童产生负面影响的母亲风险因素有关 结果，例如母亲神经心理缺陷增加， 心理困扰，以及可能改变的照顾行为。在……里面 除了记录一系列婴儿结局外，这项拟议的研究还旨在 评估环境和母体心理与妊娠结局的相关性 在英国，接触过摇头丸的儿童。拟议的研究将达到 这一目标是通过在凯斯韦斯特大学的研究人员之间建立合作伙伴关系来实现的 俄亥俄州克利夫兰的储备大学和社区研究伙伴 东伦敦大学，英国，在那里MDMA的使用很普遍，而且足够 可以招募接触MDMA的婴儿的样本量。 150名婴儿(75名接触MDMA；75名未接触)和他们的母亲将在 1个月、4个月、12个月、18个月和24个月 生长、认知、运动、语言和行为结果。接触MDMA将 由母亲的自我报告测量确定(并由头发证实 分析)，所有儿童都来自同一种族/社会阶层人口。 母亲的身份将通过社区医生在怀孕早期确定 尽可能或在婴儿出生时和评估的物质使用量和频率 每三个月。人口统计、医学和产前物质暴露将 从图表回顾、临床访谈和毛发分析中注意到。 评估母亲心理状况的标准化问卷， 人格、社会支持、智力和照顾史 将会被实施。对儿童游戏和母婴的录像观察 将进行互动。 数据将进行描述性评估，并通过一系列纵向 混合模型分析和分层多元/Logistic回归分析 描述接触MDMA的婴儿及其母亲到2岁时的功能 年龄，以及MDMA和其他物质暴露对婴儿的相对影响 结果、母亲心理功能和照料互动。 使用HLM或Structure的婴儿风险随时间的变化和预测模型 方程式模型，将被利用。拟议的研究将提供 关于胎儿接触MDMA的早期发育后遗症的信息 母亲的心理状态和照看行为可以指导儿童 设计有效的孕产妇药物治疗和儿童干预方案。

DESCRIPTION: (provided by applicant) 3-4Methylenedioxymethamphetamine (MDMA/Ecstasy) use is widespread among young adults throughout Europe and increasing in popularity in the United States among similar populations with resultant concern over the long-term negative effects of fetal MDMA exposure on the developing child. Use of MDMA is also associated with other maternal risk factors which can negatively affect child outcomes, such as increased maternal neuropsychological deficits, greater psychological distress, and potentially altered care-giving behavior. In addition to documenting a range of infant outcomes, the proposed study aims to assess environmental and maternal psychological correlates of outcomes in MDMA-exposed children in the United Kingdom. The proposed study will achieve this aim through establishing a partnership between researchers at Case Western Reserve University in Cleveland, Ohio and community research partners at the University of East London, England where MDMA use is prevalent and an adequate sample size of MDMA exposed infants can be recruited. 150 infants (75 MDMA-exposed; 75 non-exposed) and their mothers will be seen at 1 month, 4 months, 12 months, 18 and 24 months and assessed on measures of growth, cognitive, motor, language, and behavioral outcomes. MDMA exposure will be determined by maternal self-report measures (and corroborated by hair analysis), with all children drawn from the same race/social class population. Mothers will be identified through community physicians as early in pregnancy as possible or at child birth and substance use quantity and frequency assessed at each trimester. Demographic, medical, and prenatal substance exposure will be noted from chart review and clinical interview and hair analysis. Standardized questionnaires assessing maternal psychological status, personality, social supports, intellectual ability, and history of caregiving will be administered. Videotaped observations of child play and maternal child interactions will be conducted. Data will be evaluated descriptively, and through a series of longitudinal mixed model analyses and hierarchical multiple/logistic regression analyses to describe the functioning of MDMA-exposed infants and their mothers to 2 years of age, and the relative impact of MDMA and other substance exposures to infant outcomes, maternal psychological functioning, and caregiving interactions. Changes over time and predictive models of infant risk, using HLM or structural equation models, will be utilized. The proposed research will provide information about the early developmental sequelae of fetal MDMA-exposure and maternal psychological status and caregiving behaviors which can guide the design of effective maternal drug treatment and child intervention programs.